1. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. (28th October 2013) Authors: Gandhi, Anita K.; Mendy, Derek; Waldman, Michelle; Chen, Gengxin; Rychak, Emily; Miller, Karen; Gaidarova, Svetlana; Ren, Yan; Wang, Maria; Breider, Michael; Carmel, Gilles; Mahmoudi, Afshin; Jackson, Pilgrim; Abbasian, Mahan; Cathers, Brian E.; Schafer, Peter H.; Daniel, Tom O.; Lopez‐Girona, An... Journal: British journal of haematology Issue: Volume 164:Number 2(2014:Jan.) Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma. (23rd February 2016) Authors: Rychak, Emily; Mendy, Derek; Shi, Tao; Ning, Yuhong; Leisten, Jim; Lu, Ling; Miller, Karen; Narla, Rama K.; Orlowski, Robert Z.; Raymon, Heather K.; Bjorklund, Chad C.; Thakurta, Anjan; Gandhi, Anita K.; Cathers, Brian E.; Chopra, Rajesh; Daniel, Thomas O.; Lopez‐Girona, Antonia Journal: British journal of haematology Issue: Volume 172:Number 6(2016) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗